Imatinib
Chemical compound
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
18
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
Imatinib: A Viewpoint by Brian J. Druker
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o
Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
